Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

Key Points

• To evaluate the impact of trastuzumab combined with adjuvant chemotherapy on overall survival in early-stage HER2-positive breast cancer.
• Planned joint analysis of two studies: NSABP B-31 and NCCTG N9831.
• Participants received trastuzumab in addition to paclitaxel after doxorubicin and cyclophosphamide.
• Analysis focused on overall survival and cancer recurrence rates.
• Trastuzumab improved overall survival among participants, substantially reducing cancer recurrence.
• The analysis demonstrated sustained improvements in survival outcomes over time.